These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 20863426)

  • 1. An update on disordered iron metabolism and iron overload.
    Ward R
    Hematology; 2010 Oct; 15(5):311-7. PubMed ID: 20863426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A; Felisi M; De Sanctis V; De Mattia D
    Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron mobilization using chelation and phlebotomy.
    Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
    J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 6. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
    Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of long term iron chelation treatment with deferoxamine.
    Davis BA; Porter JB
    Adv Exp Med Biol; 2002; 509():91-125. PubMed ID: 12572991
    [No Abstract]   [Full Text] [Related]  

  • 10. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron Chelation Therapy as a Modality of Management.
    Aydinok Y
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term deferiprone chelation therapy.
    Hoffbrand VA; Wonke B
    Adv Exp Med Biol; 2002; 509():127-39. PubMed ID: 12572992
    [No Abstract]   [Full Text] [Related]  

  • 13. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early cardiac iron overload in children with transfusion-dependent anemias.
    Fernandes JL; Fabron A; Verissimo M
    Haematologica; 2009 Dec; 94(12):1776-7. PubMed ID: 19815835
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT; Tsai CH; Wu KH
    Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
    Kontoghiorghes GJ; Kolnagou A; Skiada A; Petrikkos G
    Hemoglobin; 2010 Jun; 34(3):227-39. PubMed ID: 20524813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron chelation with oral deferiprone in patients with thalassemia.
    Cohen AR; Martin MB
    N Engl J Med; 1998 Dec; 339(23):1713-4. PubMed ID: 9867542
    [No Abstract]   [Full Text] [Related]  

  • 18. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
    Wu KH; Chang JS; Tsai CH; Peng CT
    Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cardiac iron overload in thalassemia major.
    Westwood M; Anderson LJ; Pennell DJ
    Haematologica; 2003 May; 88(5):481-2. PubMed ID: 12745264
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.